BICO Group AB (publ)
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BICO Group AB (publ) (STO:BICO), a Swedish bio-convergence company founded in 2016 and headquartered in Gothenburg, develops, manufactures and sells hardware, laboratory automation software and related consumables for life science applications including 3D bioprinting, cell imaging, single-cell dispensing, liquid handling and workflow orchestration; its core offerings span the Bioprinting segment with 3D bioprinters such as the BIO X6 and bioinks like high-density collagen from CELLINK and Advanced BioMatrix; the Life Science Solutions segment with hybrid microscopes like the Revolution from Discover Echo, single-cell and spheroid dispensers such as the UP.SIGHT and spheroONE from CYTENA and Cellenion, and liquid handling instruments including I.DOT from DISPENDIX; and the Lab Automation segment featuring the Green Button Go Suite software for connected lab workflows from Biosero, automated mixing solutions like BioShake from QInstruments, and precision dispensing systems such as sciFLEXARRAYER from SCIENION. The company serves pharmaceutical, biotechnology, diagnostics, academic research and cosmetics sectors across North America, Europe, Asia and over 25 countries worldwide through direct sales organizations and distributors, with more than 46,000 instruments in the field and 12,000 customer publications citing its brands. In recent developments, BICO completed divestitures of MatTek and Visikol post-Q2 2025 to strengthen its balance sheet and sharpen focus on lab automation and high-demand workflows; announced an impairment and preliminary Q3 2025 figures in November 2025; secured a 15.2 MUSD contract in September 2025 for Biosero to develop integrated lab automation solutions; divested Nanoscribe in November 2024; appointed Maria Rankka as Board Chair and Lars Risberg as General Counsel in 2025; and launched Strategy 2.0 in September 2024 emphasizing sustainable profitable growth as the first-choice lab automation partner for pharma and biotech.
BICO Group AB (publ) (BCCOY) Q1 2026 Earnings Call Transcript
BICO Group AB (publ) (BCCOY) Q4 2025 Earnings Call Transcript
BICO Group AB (publ) (BCCOY) Q3 2025 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q2 2025 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q1 2025 Earnings Call Transcript
BICO Group AB (CLLKF) Q4 2024 Earnings Call Transcript
BICO Group AB (CLLKF) Q3 2024 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q2 2024 Earnings Call Transcript
Lab Instrument Industry Update - New Commercial Entrants
BICO Group AB (publ) (CLLKF) Q1 2024 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q2 2023 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q1 2023 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q4 2022 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) Q3 2022 Earnings Call Transcript
BICO Group AB (publ) (CLLKF) CEO Erik Gatenholm on Q2 2022 Results - Earnings Call Transcript
BICO Group's (CLLKF) CEO Erik Gatenholm on Q4 2021 Results - Earnings Call Transcript
BICO Group Stock Is Worth a Look